The leadership changes just keep on coming at GlaxoSmithKline. The latest? Global pharma president Abbas Hussain is out, and AstraZeneca vet Luke Miels is in.
Hussain has decided to leave the company and will make his exit later this year, GSK said Thursday without specifying a date. When he does, Miels, currently EVP of AstraZeneca’s European business, will step in.
The move will mark the end of eight-plus years at GSK for Hussain, whom the company credits with building the world’s No. 1 pharma business by volume and implementing its new, quota-free sales model across 100 countries.
Hussain is hardly the only long-tenured GSK exec headed for the door. Since CEO Andrew Witty announced last year that he would be turning over the reins this March, both vaccines chairman Moncef Slaoui and ViiV head Dominique Limet have decided to bid the company farewell.
“Succession processes are challenging for everyone involved and, unfortunately, it is rare that all of those involved stay with the company,” Witty said in a statement.
GSK, though, is hoping for big things from Miels, who launched cancer-fighter Tagrisso and jump-started growth of key heart med Brilinta at AstraZeneca. Glaxo will need his commercial smarts to keep the ball rolling on its own new launches, which have slowly but surely grown enough to start filling the gap left by waning giant Advair—especially with incoming CEO Emma Walmsley, whose own background lies in consumer health, at the helm.
“We are now entering a critical period of commercialization for our new pharmaceutical products and, over the next two to three years, we have important data to come on our early-stage pipeline,” Walmsley said in a statement. “Luke will bring a strong new voice to the decisions and choices we will have to make.”
And as the British pharma giant’s chief strategy officer, David Redfern, figures, those decisions will be many. Walmsley is “taking the time during the transition to really understand the business, and obviously she’s spending most of her time on the pharma side, … particularly R&D,” he told FiercePharma in an interview during the J.P. Morgan Healthcare Conference.
But “we have a lot of science” outside of the company’s anchor respiratory and HIV businesses—including cardiovascular and gene therapy programs, he noted—“so what choices we make and when over the next few years is a big question.”
By Carly Helfand
Source: Fierce Pharma
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”